Pyoderma gangrenosum

This study tests whether bimekizumab, a drug already approved for other skin conditions, can help heal wounds in people with pyoderma gangrenosum (PG), a rare and painful skin disorder. Adults with PG will receive injections of bimekizumab every few weeks for 24 weeks. The main g…

This study will test hyperbaric oxygen therapy (HBOT) — breathing pure oxygen in a pressurized chamber — for over 30 conditions, including long COVID, Crohn's disease, frostbite, and multiple sclerosis. Researchers will track 100 patients to see if HBOT improves their quality of …

This phase 2 study tests an injection called SHR-1139 in 20 adults with pyoderma gangrenosum, a rare condition causing painful skin ulcers. The goal is to see if the drug can completely close the ulcers and how safe it is. Researchers will also measure how the body processes the …

This phase 2 trial tests an injection called SHR-1139 in 10 adults with ulcerative pyoderma gangrenosum, a rare skin condition that causes painful, open sores. The main goal is to see if the drug can completely close the target ulcer within 12 weeks. Researchers will also check f…

This study aims to better understand rare autoinflammatory diseases by developing blood tests that measure inflammation markers. Researchers will analyze blood samples from 60 adults and children with these conditions. The goal is to identify specific inflammation pathways, which…